Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN035-ELP(V)
- Development stage
- Preclinical
- Lead developer
- AlphaMab Oncology
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
KN035-ELP(V) is a genetically engineered fusion protein combining the KN035 nanobody, which specifically binds to human programmed cell death protein ligand 1 (PD-L1), with a thermosensitive elastin-like polypeptide (ELP(V)). This design creates a super-long-acting anti-PD-L1 nanobody that forms a sustained-release depot after intraperitoneal injection, extending its circulating half-life and enhancing tumor accumulation and penetration. It is under investigation primarily for cancer immunotherapy, notably triple-negative breast cancer (TNBC), and shows improved antitumor efficacy and reduced adverse effects compared to KN035 and KN035-Fc. Its mechanism centers on efficient immune checkpoint blockade by inhibiting the PD-1/PD-L1 interaction, leading to durable antitumor immunity[1].
- Other names
- KN035-ELP(V)
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on KN035-ELP(V).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN035-ELP(V).